Summary

Week 144 secondary end point results from a randomized, double-blind, double-dummy, active-controlled study involving 700 treatment-naïve HIV-1-infected patients have reaffirmed that cobicistat can be substituted for ritonavir in a drug regimen that seeks to boost the pharmacologic effect of atazanavir in combination with emtricitabine-tenofovir disoproxil fumarate.